Listen to this article
Estimated 1 minute
The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results.
A generic semaglutide injection to promote weight loss is now approved in Canada, Health Canada says.
The regulator said the product submission, called Svemia, was filed by Canadian-based Apotex and is a generic version of the brand name drug Wegovy, sold by Denmark’s Novo Nordisk
Monday’s announcement by Health Canada marks its third such generic semaglutide product approval.
Health Canada said Svemia is approved for use once a week to treat people age 12 and older for chronic weight management in combination with a reduced-calorie diet and increased physical activity
The first two generic semaglutide injections were to treat Type 2 diabetes in adults.
Early studies suggest GLP-1s, such as Ozempic, could help reduce the risk of some cancers, but scientists say there are still more questions than answers and more long-term studies are needed to really understand the potential.
Generic versions of Novo Nordisk’s Ozempic from India-based Dr. Reddy’s Laboratories and Apotex were approved earlier this year.
Health Canada noted it’s reviewing six other submissions for generic semaglutide from different companies.
